- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Dirk Arnold on Sirflox Study Results in Colorectal Cancer
Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.
Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the phase III Sirflox study, which looked at selective internal radiation therapy (SIRT) using Yttrium-90 (Y-90) resin microspheres for the treatment of metastatic colorectal cancer.
The trial included 530 randomized patients, half that received standard chemotherapy, which is FOLFOX6 with or without bevacizumab. The other half received Y-90 SIRT, which was given after the first or second administration of FOLFOX6 with or without bevacizumab. This treatment is for the palliative patient, said Arnold.
The results were surprising, said Arnold. There was no improvement in progression-free survival when all patients were taken into consideration. However, progression of the liver was significantly reduced with SIRT. This may be because many of the patients in the trial had disease in more than just the liver, which was not effected by the SIRT, said Arnold.
<<<